Nowe strategie terapeutyczne choroby Alzheimera
References
- Aducanumab. https://www.alzforum.org/therapeutics/aducanumab (03.03.2020)
- Alam J., Blackburn K., Patrick D.: Neflamapimod: Clinical phase 2b-ready oral small molecule inhibitor of p38α to reverse synaptic dysfunction in early Alzheimer’s disease. J. Prev. Alzheimers Dis., 2017; 4: 273–278
- Amirrad F., Bousoik E., Shamloo K., Al-Shiyab H., Nguyen V.H., Montazeri Aliabadi H.: Alzheimer’s disease: Dawn of a new era? J. Pharm. Pharm. Sci., 2017; 20: 184–225
- Arndt J.W., Qian F., Smith B.A., Quan C., Kilambi K.P., Bush M.W., Walz T., Pepinsky R.B., Bussière T., Hamann S., Cameron T.O., Weinreb P.H.: Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci. Rep., 2018; 8: 6412
- Axon announces positive results from phase II ADAMANT trial for AADvac1 in Alzheimer’s disease. https://www.prnewswire.com/news-releases/axon-announces-positive-results-from-phase-ii-adamant-trial-for-aadvac1-in-alzheimers-disease-300914509.html (03.03.2020)
- Bachstetter A.D., Xing B., de Almeida L., Dimayuga E.R., Watterson D.M., Van Eldik L.J.: Microglial p38α MAPK is a key regulator of pro-inflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J. Neuroinflammation, 2011; 8: 79
- Bakota L., Brandt R.: Tau biology and tau-directed therapies for Alzheimer’s disease. Drugs, 2016; 76: 301–313
- Baranowska U., Wiśniewska R.J.: Receptor nikotynowy α7-nACh i jego znaczenie w funkcjonowaniu pamięci oraz wybranych chorobach ośrodkowego układu nerwowego. Postępy Hig. Med. Dośw., 2017; 71: 633–648
- Bearer E.L., Wu C.: Herpes simplex virus, Alzheimer’s disease and a possible role for Rab GTPases. Front. Cell Dev. Biol., 2019; 7: 134
- Boese A.C., Hamblin M.H., Lee J.P.: Neural stem cell therapy for neurovascular injury in Alzheimer’s disease. Exp. Neurol., 2020; 324: 113112
- Buee L.: Dementia therapy targeting tau. Adv. Exp. Med. Biol., 2019; 1184: 407–416
- Bursavich M.G., Harrison B.A., Blain J.F.: Gamma secretase modulators: New Alzheimer’s drugs on the horizon? J. Med. Chem., 2016; 59: 7389–7409
- Caraci F., Leggio G.M., Salomone S., Drago F.: New drugs in psychiatry: Focus on new pharmacological targets. F1000Res., 2017; 6: 397
- Cebers G., Alexander R.C., Haeberlein S.B., Han D., Goldwater R., Ereshefsky L., Olsson T., Ye N., Rosen L., Russell M., Maltby J., Eketjäll S., Kugler A.R.: AZD3293: Pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer’s disease. J. Alzheimers Dis., 2017; 55: 1039–1053
- Crenezumab. https://www.alzforum.org/therapeutics/crenezumab (03.03.2020)
- Cummings J., Lee G., Ritter A., Sabbagh M., Zhong K.: Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement., 2019; 5: 272–293
- Cummings J.L., Tong G., Ballard C.: Treatment combinations for Alzheimer’s disease: Current and future pharmacotherapy options. J. Alzheimers Dis., 2019; 67: 779–794
- Degterev A., Ofengeim D., Yuan J.: Targeting RIPK1 for the treatment of human diseases. Proc. Natl. Acad. Sci. USA, 2019; 116: 9714– 9722
- DeVos S.L., Miller R.L., Schoch K.M., Holmes B.B., Kebodeaux C.S., Wegener A.J., Chen G., Shen T., Tran H., Nichols B., Zanardi T.A., Kordasiewicz H.B., Swayze E.E., Bennett C.F., Diamond M.I. i wsp.: Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med., 2017; 9: eaag0481
- Dominy S.S., Lynch C., Ermini F., Benedyk M., Marczyk A., Konradi A., Nguyen M., Haditsch U., Raha D., Griffin C., Holsinger L.J., Arastu-Kapur S., Kaba S., Lee A., Ryder M.I. i wsp.: Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv., 2019; 5: eaau3333
- Dong Y., Li X., Cheng J., Hou L.: Drug development for Alzheimer’s disease: Microglia induced neuroinflammation as a target? Int. J. Mol. Sci., 2019; 20: 558
- Egan M.F., Kost J., Voss T., Mukai Y., Aisen P.S., Cummings J.L., Tariot P.N., Vellas B., van Dyck C.H., Boada M., Zhang Y., Li W., Furtek C., Mahoney E., Harper Mozley L. i wsp.: Randomized trial of verubecestat for prodromal Alzheimer’s disease. N. Engl. J. Med., 2019; 380: 1408–1420
- Elayta. https://www.alzforum.org/therapeutics/elayta (03.03.2020)
- Elenbecestat. https://www.alzforum.org/therapeutics/elenbecestat (03.03.2020)
- Farlow M.R., Andreasen N., Riviere M.E., Vostiar I., Vitaliti A., Sovago J., Caputo A., Winblad B., Graf A.: Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease. Alzheimers Res. Ther., 2015; 7: 23
- Femminella G.D., Frangou E., Love S.B., Busza G., Holmes C., Ritchie C., Lawrence R., McFarlane B., Tadros G., Ridha B.H., Bannister C., Walker Z., Archer H., Coulthard E., Underwood B.R. i wsp.: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: Study protocol for a randomised controlled trial (ELAD study). Trials, 2019; 20: 191
- Gantenerumab. https://www.alzforum.org/therapeutics/gantenerumab (03.03.2020)
- Gaweł M., Potulska-Chromik A.: Choroby neurodegeneracyjne: Choroba Alzheimera i Parkinsona. Postępy Nauk Med., 2015; 7: 468–476
- Ge M., Zhang Y., Hao Q., Zhao Y., Dong B.: Effects of mesenchymal stem cells transplantation on cognitive deficits in animal models of Alzheimer’s disease: A systematic review and meta-analysis. Brain Behav., 2018; 8: e00982
- George T.P.: Nicotinic receptor mechanisms in neuropsychiatric disorders: Therapeutic implications. Prim. Psychiatry, 2010; 17: 35–41
- Ghosh A.K., Cárdenas E.L., Osswald H.L.: The design, development, and evaluation of BACE1 inhibitors for the treatment of Alzheimer’s disease. W: Alzheimer’s Disease II. Topics in Medicinal Chemistry, vol 24, red.: M. Wolfe. Springer International Publishing, Cham 2016, 27–85
- Godyń J., Jończyk J., Panek D., Malawska B.: Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol. Rep., 2016; 68: 127–138
- Gratuze M., Leyns C.E.G., Holtzman D.M.: New insights into the role of TREM2 in Alzheimer’s disease. Mol. Neurodegener., 2018; 13: 66
- Hampel H., Mesulam M.M., Cuello A.C., Farlow M.R., Giacobini E., Grossberg G.T., Khachaturian A.S., Vergallo A., Cavedo E., Snyder P.J., Khachaturian Z.S.: The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain, 2018; 141: 1917–1933
- Hull M., Sadowsky C., Arai H., Le Prince Leterme G., Holstein A., Booth K., Peng Y., Yoshiyama T., Suzuki H., Ketter N., Liu E., Ryan J.M.: Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer’s disease. Curr. Alzheimer Res., 2017; 14: 696–708
- Hung S.Y., Fu W.M.: Drug candidates in clinical trials for Alzheimer’s disease. J. Biomed. Sci., 2017; 24: 47
- Jadhav S., Avila J., Schöll M., Kovacs G.G., Kövari E., Skrabana R., Evans L.D., Kontsekova E., Malawska B., de Silva R., Buee L., Zilka N.: A walk through tau therapeutic strategies. Acta Neuropathol. Commun., 2019; 7: 22
- Kowalski K., Mulak A.: Brain-gut-microbiota axis in Alzheimer’s disease. J. Neurogastroenterol. Motil., 2019; 25: 48–60
- Krstic D., Knuesel I.: Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol., 2013; 9: 25–34
- Lacosta A.M., Pascual-Lucas M., Pesini P., Casabona D., Pérez-Grijalba V., Marcos-Campos I., Sarasa L., Canudas J., Badi H., Monleón I., San-José I., Munuera J., Rodríguez-Gómez O., Abdelnour C., Lafuente A. i wsp.: Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, phase I trial. Alzheimers Res. Ther., 2018; 10: 12
- Lee J.K., Kim N.J.: Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease. Molecules, 2017; 22: 1287–1310
- Lopez Lopez C., Caputo A., Liu F., Riviere M.E., Rouzade-Dominguez M.L., Thomas R.G., Langbaum J.B., Lenz R., Reiman E.M., Graf A., Tariot P.N.: The Alzheimer’s Prevention Initiative Generation Program: Evaluating CNP520 efficacy in the prevention of Alzheimer’s disease. J. Prev. Alzheimers Dis., 2017; 4: 242–246
- Maia M.A., Sousa E.: BACE-1 and γ-secretase as therapeutic targets for Alzheimer’s disease. Pharmaceuticals, 2019; 12: E41
- Marszałek M.: Choroba Alzheimera a produkty degradacji białka APP. Formowanie i różnorodność form fibrylujących peptydów – wybrane aspekty. Postępy Hig. Med. Dośw., 2016; 70: 787–796
- Marszałek M.: Cukrzyca typu 2 a choroba Alzheimera – jedna czy dwie choroby? Mechanizmy asocjacji. Postępy Hig. Med. Dośw., 2013; 67: 653–671
- Medina M.: An overview on the clinical development of tau-based therapeutics. Int. J. Mol. Sci., 2018; 19: 1160
- Novak P., Schmidt R., Kontsekova E., Kovacech B., Smolek T., Katina S., Fialova L., Prcina M., Parrak V., Dal-Bianco P., Brunner M., Staffen W., Rainer M., Ondrus M., Ropele S. i wsp.: FUNDAMANT: An interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease. Alzheimers Res. Ther., 2018; 10: 108
- Okamoto M., Gray J.D., Larson C.S., Kazim S.F., Soya H., McEwen B.S., Pereira A.C.: Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer’s disease. Transl. Psychiatry, 2018; 8: 153
- Panza F., Lozupone M., Watling M., Imbimbo B.P.: Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? Expert Rev. Neurother., 2019; 19: 599–602
- Pasinetti G.M., Wang J., Ho L., Zhao W., Dubner L.: Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment. Biochim. Biophys. Acta, 2015; 1852: 1202–1208
- Payesko J.: GRF6019 Shows Positive Phase 2 Results in Mild to Moderate Alzheimer Disease. https://www.neurologylive.com/clinical-focus/grf6019-shows-positive-phase-2-results-in-mild-to-moderate-alzheimer-disease (03.03.2020)
- Petrov A.M., Lam M., Mast N., Moon J., Li Y., Maxfield E., Pikuleva I.A.: CYP46A1 Activation by efavirenz leads to behavioral improvement without significant changes in amyloid plaque load in the brain of 5XFAD mice. Neurotherapeutics, 2019; 16: 710–724
- Safieh M., Korczyn A.D., Michaelson D.M.: ApoE4: An emerging therapeutic target for Alzheimer’s disease. BMC Med., 2019; 17: 64
- Sanabria-Castro A., Alvarado-Echeverría I., Monge-Bonilla C.: Molecular pathogenesis of Alzheimer’s disease: An update. Ann. Neurosci., 2017; 24: 46–54
- Shaikh S., Rizvi S.M., Shakil S., Riyaz S., Biswas D., Jahan R.: Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders. Biotechnol. Appl. Biochem., 2016; 63: 145–150
- Siopi E., Llufriu-Dabén G., Cho A.H., Vidal-Lletjós S., Plotkine M., Marchand-Leroux C., Jafarian-Tehrani M.: Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuro-protection following traumatic brain injury in mice. Neuropharmacology, 2013; 67: 183–192
- Smith A.: Positive results for UB-311 Alzheimer’s vaccine. http://www.pharmatimes.com/news/positive_results_for_ub-311_alzheimers_vaccine_1275579 (03.03.2020)
- Solanezumab. https://www.alzforum.org/therapeutics/solanezumab (03.03.2020)
- The New Chinese Alzheimer’s Drug (GV-971) Making its Way to Global Trials: Material Science or Marketing?. https://www.trialsitenews.com/the-new-chinese-alzheimers-drug-gv-971-making-its-way-to-global-trials-material-science-or-marketing/ (25.05.2020)
- TPI 287. https://www.alzforum.org/therapeutics/tpi-287 (03.03.2020)
- Traneurocin Phase 2A Trial Results Show Improvements for People With Mild Cognitive Impairment. https://practicalneurology.com/index.php/news/traneurocin-phase-2a-trial-results-show-improvements-for-people-with-mild-cognitive-impairment (03.03.2020)
- Umibecestat. https://www.alzforum.org/therapeutics/umibecestat (03.03.2020)
- Vellas B., Coley N., Ousset P.J., Berrut G., Dartigues J.F., Dubois B., Grandjean H., Pasquier F., Piette F., Robert P., Touchon J., Garnier P., Mathiex-Fortunet H., Andrieu S., GuidAge Study Group: Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): A randomised placebo-controlled trial. Lancet Neurol., 2012; 11: 851–859
- Verma S., Kumar A., Tripathi T., Kumar A.: Muscarinic and nicotinic acetylcholine receptor agonists: Current scenario in Alzheimer’s disease therapy. J. Pharm. Pharmacol., 2018; 70: 985–993
- Wang X., Sun G., Feng T., Zhang J., Huang X., Wang T., Xie Z., Chu X., Yang J., Wang H., Chang S., Gong Y., Ruan L., Zhang G., Yan S. i wsp.: Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res., 2019; 29: 787–803
- Wisniewski T., Drummond E.: Developing therapeutic vaccines against Alzheimer’s disease. Expert Rev. Vaccines, 2016; 15: 401–415
- Wojsiat J., Zoltowska K.M., Laskowska-Kaszub K., Wojda U.: Oxidant/antioxidant imbalance in Alzheimer’s disease: Therapeutic and diagnostic prospects. Oxid. Med. Cell. Longev., 2018; 2018: 6435861
- Xicota L., Rodriguez-Morato J., Dierssen M., de la Torre R.: Potential role of (-)-epigallocatechin-3-gallate (EGCG) in the secondary prevention of Alzheimer disease. Curr. Drug Targets, 2017; 18: 174–195
- Zhang C., Griciuc A., Hudry E., Wan Y., Quinti L., Ward J., Forte A.M., Shen X., Ran C., Elmaleh D.R., Tanzi R.E.: Cromolyn reduces levels of the Alzheimer’s disease-associated amyloid β-protein by promoting microglial phagocytosis. Sci. Rep., 2018; 8: 1144
- Zhang Y., Li P., Feng J., Wu M.: Dysfunction of NMDA receptors in Alzheimer’s disease. Neurol. Sci., 2016; 37: 1039–1047
- Zhao Y., Zhao B.: Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid. Med. Cell. Longev., 2013; 2013: 316523
DOI: https://doi.org/10.5604/01.3001.0014.9532 | Journal eISSN: 1732-2693
Language: English
Page range: 474 - 490
Submitted on: Mar 13, 2020
Accepted on: Jan 15, 2021
Published on: Jun 21, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2021 Dominika Nowak, Wojciech Słupski, Maria Rutkowska, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.